Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD.
The item "Ebitda-Per-Share" stands at 16.58 United States Dollars as of 09/30/2025, the highest value at least since 06/30/2022, the period currently displayed.
As of the end of Johnson & Johnson's third quarter, the item "Ebitda Per Share" stands at 16.58 USD. This represents an increase of 13.04 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 56.61 percent compared to the value the year prior.
The 1 year change in percent is 56.61.
The 3 year change in percent is 35.65.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Ebitda Per Share | 905,699,262,464.00 |
![]() | AbbVie Inc - Ebitda Per Share | 399,570,305,024.00 |
![]() | Roche Holding AG - Ebitda Per Share | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Ebitda Per Share | 280,205,508,085.11 |
![]() | Novartis AG - Ebitda Per Share | 255,096,620,580.91 |